TATA HEALTH (01255) announced its 2023 annual results, reporting revenue of approximately HK$207.5 million, representing a year-over-year increase of about 43.5%. The company recorded a loss attributable to owners of HK$32.294 million, marking a shift from profit to loss compared to the previous year, with a loss per share of HK$0.13. According to the announcement, the loss was primarily attributed to the healthcare and online medical services business segments, which remain in a state of long-term losses and operational stagnation.